Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

281. Association between age, deprivation and specific comorbid conditions and the receipt of major surgery in patients with non-small cell lung cancer in England: A population-based study

Association between age, deprivation and specific comorbid conditions and the receipt of major surgery in patients with non-small cell lung cancer in England: A population-based study 30100577 2018 08 13 1468-3296 2018 Aug 12 Thorax Thorax Association between age, deprivation and specific comorbid conditions and the receipt of major surgery in patients with non-small cell lung cancer in England: A population-based study. thoraxjnl-2017-211395 10.1136/thoraxjnl-2017-211395 We investigated (...) socioeconomic disparities and the role of the main prognostic factors in receiving major surgical treatment in patients with lung cancer in England. Our study comprised 31 351 patients diagnosed with non-small cell lung cancer in England in 2012. Data from the national population-based cancer registry were linked to Hospital Episode Statistics and National Lung Cancer Audit data to obtain information on stage, performance status and comorbidities, and to identify patients receiving major surgical treatment

EvidenceUpdates2018

282. Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer 29906251 2018 08 16 1527-7755 36 23 2018 Aug 10 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small (...) -Cell Lung Cancer. 2386-2394 10.1200/JCO.2018.77.7672 Purpose Both temozolomide (TMZ) and poly (ADP-ribose) polymerase (PARP) inhibitors are active in small-cell lung cancer (SCLC). This phase II, randomized, double-blind study evaluated whether addition of the PARP inhibitor veliparib to TMZ improves 4-month progression-free survival (PFS). Patients and Methods A total of 104 patients with recurrent SCLC were randomly assigned 1:1 to oral veliparib or placebo 40 mg twice daily, days 1 to 7

EvidenceUpdates2018 Full Text: Link to full Text with Trip Pro

283. Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial

Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial 29989858 2018 07 10 1527-7755 2018 Jul 10 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled (...) Trial. JCO2018777847 10.1200/JCO.2018.77.7847 Purpose The contribution of adjuvant chemotherapy after chemoradiation therapy (CRT) in nasopharyngeal cancer (NPC) remains controversial. Plasma Epstein-Barr virus (EBV) DNA is a potential biomarker of subclinical residual disease in NPC. In this prospective, multicenter, randomized controlled trial, we used plasma EBV DNA to identify patients with NPC at a higher risk of relapse for adjuvant chemotherapy. Patients and Methods Eligible patients

EvidenceUpdates2018

284. Axalimogene filolisbac (Raligize) - cervical cancer

Axalimogene filolisbac (Raligize) - cervical cancer 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 27 July 2018 EMA/499771/2018 EMEA/H/C/004473 Withdrawal of the marketing authorisation application for Raligize (axalimogene (...) filolisbac) On 10 July 2018, FGK Representative Service GmbH officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Raligize, for the treatment of cancer of the cervix (the neck of the womb). What is Raligize? Raligize is a cancer medicine containing the active substance axalimogene filolisbac. It was to be available as a concentrate for making up an infusion (drip) to be given into a vein. Raligize

European Medicines Agency - EPARs2018

285. Nivolumab (Opdivo) - to treat stomach cancer, including cancers that occur at the junction of the stomach and oesophagus

Nivolumab (Opdivo) - to treat stomach cancer, including cancers that occur at the junction of the stomach and oesophagus 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 27 July 2018 EMA/504630/2018 EMEA/H/C/003985/II/0039 (...) Withdrawal of application for a change to the marketing authorisation for Opdivo (nivolumab) On 27 June 2018, Bristol-Myers Squibb Pharma EEIG officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a new use of Opdivo for the treatment of stomach cancer. What is Opdivo? Opdivo is a cancer medicine currently authorised to treat the following cancers: melanoma (skin cancer), non-small cell lung cancer, renal cell carcinoma (kidney cancer

European Medicines Agency - EPARs2018

286. Sunitinib (Sutent) - to delay or prevent the return of kidney cancer

Sunitinib (Sutent) - to delay or prevent the return of kidney cancer 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 27 July 2018 EMA/504631/2018 EMEA/H/C/000687/II/0065 Withdrawal of application for a change to the marketing (...) authorisation for Sutent (sunitinib) On 26 June 2018, Pfizer Limited officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application to extend use of Sutent to the treatment of patients at high risk of kidney cancer returning after surgery. What is Sutent? Sutent is a cancer medicine currently authorised for treating the following cancers: • gastrointestinal stromal tumour (a cancer of the stomach and bowel); • pancreatic neuroendocrine tumours

European Medicines Agency - EPARs2018

287. Neratinib (Nerlynx) - Breast cancer, breast neoplasms

Neratinib (Nerlynx) - Breast cancer, breast neoplasms 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 13 July 2018 EMA/CHMP/525204/2018 Committee for Medicinal Products for Human Use (CHMP) Assessment report Nerlynx International (...) disease-free survival DFS-DCIS disease-free survival including ductal carcinoma in situ ECG electrocardiogram ECOG Eastern Cooperative Oncology Group EGFR epidermal growth factor receptor EQ-5D EuroQol 5-Dimension Questionnaire ER estrogen receptor ERBB erythroblastic leukemia viral oncogene homolog; also termed HER ExteNET Extended Adjuvant Treatment of Breast Cancer with Neratinib FACT-B Functional Assessment of Cancer Therapy-Breast FMO flavin-containing monooxygenase GI gastrointestinal HER human

European Medicines Agency - EPARs2018

288. Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care: a systematic review and cost-effectiveness analysis

Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care: a systematic review and cost-effectiveness analysis Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care: a systematic review and cost-effectiveness analysis Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose (...) a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} Risk scores may offer increased sensitivity compared to current practice and consequently more women with malignant tumours would be referred to a specialist, but more women with benign tumours would also be referred. {{author}} {{($index , , , , , , , & . Marie Westwood 1, * , Bram Ramaekers 2 , Shona Lang 1

NIHR HTA programme2018

289. Penile Cancer

Penile Cancer Penile Cancer | Uroweb Guidelines › Penile Cancer Penile Cancer To access the pdfs & translations of individual guidelines, please as EAU member. Non-EAU members can view the web versions. To become an EAU member, click . EAU Central Office PO Box 30016 NL-6803 AA ARNHEM The Netherlands

European Association of Urology2018

290. Non-muscle-invasive Bladder Cancer

Non-muscle-invasive Bladder Cancer Non-muscle-invasive Bladder Cancer | Uroweb Guidelines › Non-muscle-invasive Bladder Cancer Non-muscle-invasive Bladder Cancer To access the pdfs & translations of individual guidelines, please as EAU member. Non-EAU members can view the web versions. To become an EAU member, click . EAU Central Office PO Box 30016 NL-6803 AA ARNHEM The Netherlands

European Association of Urology2018

291. Muscle-invasive and Metastatic Bladder Cancer

Muscle-invasive and Metastatic Bladder Cancer Muscle-invasive and Metastatic Bladder Cancer | Uroweb Guidelines › Muscle-invasive and Metastatic Bladder Cancer Muscle-invasive and Metastatic Bladder Cancer To access the pdfs & translations of individual guidelines, please as EAU member. Non-EAU members can view the web versions. To become an EAU member, click . EAU Central Office PO Box 30016 NL-6803 AA ARNHEM The Netherlands

European Association of Urology2018

292. Testicular Cancer

Testicular Cancer Testicular Cancer | Uroweb Guidelines › Testicular Cancer Testicular Cancer To access the pdfs & translations of individual guidelines, please as EAU member. Non-EAU members can view the web versions. To become an EAU member, click . EAU Central Office PO Box 30016 NL-6803 AA ARNHEM The Netherlands

European Association of Urology2018

293. Prostate Cancer

Prostate Cancer Prostate Cancer | Uroweb Guidelines › Prostate Cancer Prostate Cancer To access the pdfs & translations of individual guidelines, please as EAU member. Non-EAU members can view the web versions. To become an EAU member, click . EAU Central Office PO Box 30016 NL-6803 AA ARNHEM The Netherlands

European Association of Urology2018

294. Optimal care pathway for Aboriginal and Torres Strait Islander people with cancer: Quick reference guide

Optimal care pathway for Aboriginal and Torres Strait Islander people with cancer: Quick reference guide This Quick Reference Guide provides guidance to health practitioners and service planners on optimal care for Aboriginal and Torres Strait Islander people with cancer, across the cancer continuum. Refer to the relevant tumour-specific Optimal Care Pathway at cancerorg.au/OCP . For Aboriginal and Torres Strait Islander people, health and connection to land, culture, community and identity (...) are intrinsically linked. Health encompasses a whole-of-life view and includes a cyclical concept of life-death-life. Please note that not all patients with cancer will follow every step of this pathway: Key considerations to support the delivery of optimal care for Aboriginal and Torres Strait Islander people with cancer: Understanding your patient • Understand the philosophies of holistic health and wellbeing and the role of Aboriginal and Torres Strait Islander knowledge, values, beliefs, cultural needs

Cancer Australia2018

295. Cervical Cancer: Screening

Cervical Cancer: Screening Final Update Summary: Cervical Cancer: Screening - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 11/16/2018 6:27:19 PM You are here: Final Summary Cervical Cancer: Screening Release Date: August 2018 Recommendation Summary Population Recommendation Grade Women aged 21 to 65 years The USPSTF recommends screening for cervical cancer every 3 years with cervical cytology alone in women aged 21 to 29 years (...) . For women aged 30 to 65 years, the USPSTF recommends screening every 3 years with cervical cytology alone, every 5 years with high-risk human papillomavirus (hrHPV) testing alone, or every 5 years with hrHPV testing in combination with cytology (cotesting). See the for the relative benefits and harms of alternative screening strategies for women 21 years or older. Women older than 65 years The USPSTF recommends against screening for cervical cancer in women older than 65 years who have had adequate

U.S. Preventive Services Task Force2018

296. Optimal Care Pathway for Aboriginal and Torres Strait Islander people with cancer

Optimal Care Pathway for Aboriginal and Torres Strait Islander people with cancer Optimal care pathway for Aboriginal and Torres Strait Islander people with cancerOptimal care pathway for Aboriginal and Torres Strait Islander people with cancerStatement of acknowledgement We acknowledge the Traditional Owners of Country throughout Australia and their continuing connection to the land, sea and community. We pay our respects to them and their cultures and to Elders past and present. This work (...) is available at cancer.org.au/ocp and canceraustralia.gov.auForeword i Summary 1 Context 5 Intent and key principles 8 Supporting the delivery of optimal care for Aboriginal and Torres Strait Islander people with cancer 18 Optimal cancer care pathway 26 Step 1: Prevention and early detection 27 Step 2: Presentation, initial investigations and referral 35 Step 3: Diagnosis, staging and treatment planning 39 Step 4: Treatment 45 Step 5: Care after initial treatment and recovery 51 Step 6: Managing recurrent

Cancer Australia2018

297. AlignRT in breast cancer radiotherapy

AlignRT in breast cancer radiotherapy AlignR AlignRT in breast cancer r T in breast cancer radiother adiotherap apy y Medtech innovation briefing Published: 24 August 2018 nice.org.uk/guidance/mib157 pathways Summary Summary The technology technology described in this briefing is the AlignRT patient position monitoring system. This briefing focuses on its use during breast cancer radiation therapy. The inno innovativ vative aspect e aspect is that it may avoid inaccurate treatment by precisely (...) in this briefing are from 4 observational studies involving a total of 228 adults in tertiary care settings in the US and Europe. They suggest that AlignRT is effective in maintaining accurate patient positioning during breast cancer radiotherapy. K Ke ey uncertainties y uncertainties are that there is no evidence from direct comparisons of AlignRT with location monitoring or from studies specifically using AlignRT as the main intervention. The cost cost of AlignRT is £150,000 to £225,000 per unit (excluding

National Institute for Health and Clinical Excellence - Advice2018

298. Hydrogel Spacer to reduce rectal toxicity in prostate cancer radiotherapy: a health technology assessment

Hydrogel Spacer to reduce rectal toxicity in prostate cancer radiotherapy: a health technology assessment Report available from http://www.muhc.ca/tau Technology Assessment Unit of the McGill University Health Centre (MUHC) Hydrogel Spacer to reduce rectal toxicity in prostate cancer radiotherapy: a health technology assessment Report number: 82 DATE: April 16, 2018 Report available from http://www.muhc.ca/tau Report prepared for the Technology Assessment Unit (TAU) of the McGill University (...) Health Centre (MUHC) by David Felipe Forero, Nisha Almeida, Nandini Dendukuri Approved by the Committee of the TAU on April 16 th , 2018 TAU Committee Andre Bonnici, James Brophy, Nandini Dendukuri, Todd Lee, Brenda MacGibbon-Taylor, Emily McDonald, Teresa Mack, Nancy Mayo, Maurice McGregor, Alyson Turner Suggested citation Forero DF, Almeida ND, Dendukuri N. Hydrogel Spacer to reduce rectal toxicity in prostate cancer radiotherapy: a health technology assessment. Montreal (Canada): Technology

McGill TAU reports2018

299. Antiandrogen Therapies for Nonmetastatic Castration-Resistant Prostate Cancer: Effectiveness and Value

Antiandrogen Therapies for Nonmetastatic Castration-Resistant Prostate Cancer: Effectiveness and Value ©Institute for Clinical and Economic Review, 2018 Antiandrogen Therapies for Nonmetastatic Castration-Resistant Prostate Cancer: Effectiveness and Value Evidence Report August 24, 2018 Prepared for ©Institute for Clinical and Economic Review, 2018 Page i Evidence Report - Antiandrogens for Nonmetastatic Castration-Resistant Prostate Cancer AUTHORS: ICER Staff/Consultants University (...) Report - Antiandrogens for Nonmetastatic Castration-Resistant Prostate Cancer About ICER The Institute for Clinical and Economic Review (ICER) is an independent non-profit research organization that evaluates medical evidence and convenes public deliberative bodies to help stakeholders interpret and apply evidence to improve patient outcomes and control costs. Through all its work, ICER seeks to help create a future in which collaborative efforts to move evidence into action provide the foundation

California Technology Assessment Forum2018

300. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study

Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study 30060256 2018 07 30 2567-689X 118 8 2018 Aug Thrombosis and haemostasis Thromb. Haemost. Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study. 1439-1449 10.1055/s-0038-1667001 In the Hokusai VTE Cancer study, edoxaban was non-inferior to dalteparin for the composite outcome of recurrent venous thromboembolism (VTE (...) ) and major bleeding in 1,050 patients with cancer-associated VTE. The absolute rate of recurrent VTE was 3.4% lower with edoxaban, whereas the absolute rate of major bleeding was 2.9% higher. The present analysis focuses on the sites, clinical presentation, course and outcome of bleeding events, and the associated tumour types. Major bleeds and their severity (categories 1-4) were blindly adjudicated by a committee using a priori defined criteria, and data were analysed in the safety population. Major

EvidenceUpdates2018